Engineered immunologic niche monitors checkpoint blockade response and probes mechanisms of resistance
ImmunoMedicine · 2024
DOI: 10.1002/imed.1052 ↗Kurz gefasst
Fachartikel in der Zeitschrift ImmunoMedicine, 2024. Verfasst von Ravi M Raghani und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIBIB NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Antibodies to programmed cell death protein 1 (anti‐PD‐1) have become a promising immunotherapy for triple negative breast cancer (TNBC), blocking PD‐L1 signaling from pro‐tumor cells through T cell PD‐1 receptor binding. Nevertheless, only 10%–20% of PD‐L1 + metastatic TNBC patients who meet criteria benefit from immune checkpoint blockade (ICB), and biomarkers to predict patient response have been elusive. We have previously developed an immunological niche, consisting of a microporous implant in the subcutaneous space, that supports tissue formation whose immune composition is consistent with that within vital organs. Herein, we investigated dynamic gene expression within this immunological niche to provide biomarkers of response to anti‐PD‐1. In a 4T1 model of metastatic TNBC, we observed sensitivity and resistance to anti‐PD‐1 based on primary tumor growth and survival. The niche was biopsied before, during, and after anti‐PD‐1 therapy, and analyzed for cell types and gene expression indicative of treatment refractivity. Myeloid cell‐to‐lymphocyte ratios were altered between ICB‐sensitivity and resistance. Longitudinal analysis of gene expression implicated dynamic myeloid cell function that stratified sensitivity from resistance. A niche‐derived gene signature predicted sensitivity or resistance prior to therapy. Analysis of the niche to monitor immunotherapy response presents a new opportunity to personalize care and investigate mechanisms underlying treatment resistance. Summary: A remote implant identified biomarkers that predict anti‐PD‐1 response before therapy, providing a unique tool to understand heterologous immunotherapy resistance in triple negative breast cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
- Department of Surgery, Washington University, St. Louis, Missouri.
- Department of Cariology, Restorative Sciences, and Endodontics, University of Michigan, Ann Arbor, Michigan.
- Department of Surgery, University of Michigan, Ann Arbor, Michigan.
- Department of Pathology, University of Michigan, Ann Arbor, Michigan.
- Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan.
Förderung
- NCI NIH HHS
- NIBIB NIH HHS
- National Institutes of Health
- Dr. Ralph and Marian Falk Medical Research Trust
Zitieren
APA
Raghani, R. M., Urie, R. R., Ma, J. A., Escalona, G., Schrack, I. A., DiLillo, K. M., Kandagatla, P., Decker, J. T., Morris, A. H., Arnold, K. B., Jeruss, J. S., & Shea, L. D. (2024). Engineered immunologic niche monitors checkpoint blockade response and probes mechanisms of resistance. ImmunoMedicine. https://doi.org/10.1002/imed.1052
Vancouver
Raghani RM, Urie RR, Ma JA, Escalona G, Schrack IA, DiLillo KM, et al. Engineered immunologic niche monitors checkpoint blockade response and probes mechanisms of resistance. ImmunoMedicine. 2024. doi:10.1002/imed.1052
BibTeX
@article{Raghani2024,
author = {Raghani, Ravi M and Urie, Russell R and Ma, Jeffrey A and Escalona, Guillermo and Schrack, Ian A and DiLillo, Katarina M and Kandagatla, Pridvi and Decker, Joseph T and Morris, Aaron H and Arnold, Kelly B and Jeruss, Jacqueline S and Shea, Lonnie D},
title = {Engineered immunologic niche monitors checkpoint blockade response and probes mechanisms of resistance},
journal = {ImmunoMedicine},
year = {2024},
doi = {10.1002/imed.1052}
}
EUVIMED